FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Washington, D.C. 20549		OMB APPROV	AL	
Section 16. Form 4 or Form 5 obligations may continue. See	T OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	ERSHIP	OMB Number: 32 Estimated average burden hours per response:	235-0287 0.5	
1. Name and Address of Reporting Person * Mullennix Stephen	2. Issuer Name and Ticker or Trading Symbol <u>UroGen Pharma Ltd.</u> [URGN]	(Check all applicabl Director	tor 10% Owner		
(Last) (First) (Middle) C/O UROGEN PHARMA LTD. 400 ALEXANDER PARK	3. Date of Earliest Transaction (Month/Day/Year) 04/26/2020	• X below) Chief	below)	2	

(Street) PRINCETON NJ

(State)

(City)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

4. If Amendment, Date of Original Filed (Month/Day/Year)

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
		Code V Amount (A) or (D)		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)			
Ordinary Shares	04/26/2020		М		417	Α	(1)	10,229	D		
Ordinary Shares	04/27/2020		S		145 ⁽²⁾	D	\$ 24.35	10,084	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nu of Deriv Secu Acqu (A) of Dispo of (D) (Instr and 5	ative rities ired r osed c 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	,) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units (RSUs)	(1)	04/26/2020		М			417	(3)	(3)	Ordinary Shares	417	\$ 0.00	2,917	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

08540

(Zip)

3. The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal guarterly installments thereafter.

Remarks:

/s/ Peter Pfreundschuh, Attorney-in-Fact

04/28/2020

In

6. Individual or Joint/Group Filing (Check Applicable

Form filed by One Reporting Person

Form filed by More than One Reporting

Line)

Х

Person

7

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.